Understanding what makes Lassa virus dangerous
Viral factors responsible for Lassa virus pathogenicity
This study is looking at the Lassa virus, which causes serious illness in West Africa, to understand how different strains of the virus make people sick and how our bodies respond, with the goal of finding better ways to prevent and treat Lassa fever.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10831563 on NIH RePORTER |
What this research studies
This research investigates the Lassa virus, which causes severe outbreaks in West Africa, focusing on the viral factors that contribute to its pathogenicity. By using a novel guinea pig model, researchers aim to identify the differences between various strains of the virus and how they affect disease severity. The study employs advanced genetic techniques to explore the host's response to the virus, which is crucial for developing effective vaccines and treatments. The findings could lead to better prevention and therapeutic strategies against Lassa fever.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in or traveling to West African regions where Lassa fever is endemic.
Not a fit: Patients who do not reside in areas affected by Lassa fever or those with no risk of exposure to the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines and treatments for Lassa fever, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in understanding viral pathogenicity through animal models, indicating potential for success in this novel approach.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Maruyama, Junki — University of Texas Med Br Galveston
- Study coordinator: Maruyama, Junki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.